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Abstract 
 
 Vasoactive intestinal peptide (VIP) is a neuroendocrine peptide that has been implicated 
in a myriad of functions. VIP promotes neuronal survival during development and apoptotic 
challenges. Further, VIP has been shown to regulate hormonal release, circadian rhythms, 
vasodilation, and T cell proliferation in central and peripheral tissues. VIP binds with equally 
high affinity to VPAC1 and VPAC2 receptors, members of the Class B family of G protein-
coupled receptors (GPCRs) that also include the PAC1, glucagon (GCGR), and CRH receptors. 
VIP binding has previously been shown to increase downstream MAPK signaling cascades, 
especially MEK/ERK. Given the structural similarities and functional overlap between VPAC1 
and VPAC2 receptors, we sought to investigate whether there are small molecule modulators that 
can probe and identify the functional distinctions between the two receptor subtypes. For these 
studies, we used HEK-293 cells stably expressing the VPAC1-EGFP or the VPAC2-EGFP 
receptor. The cultures were treated with VIP with and without the addition of putative small 
molecule antagonists. Protein assays and western blotting analysis for phosphorylated ERK 
(pERK) were performed to define quantitative changes in ERK activation. Many compounds in 
the small molecule panel were non-selective antagonists at the VPAC1 and VPAC2 receptors. 
Interestingly, an acyl hydrazide compound, I48, and a previously described glucagon receptor 
antagonist, MK-0893, behaved as positive allosteric modulators at the VPAC1 receptor on ERK 
activation, but not at the VPAC2 receptor. Our results suggest that these compounds can uniquely 
restrict the conformational microstate of the VPAC1 receptor to amplify VIP-mediated ERK 
signaling.   
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VIP is a neuroendocrine peptide that was first isolated from porcine small intestines (Said 
& Mutt, 1970). The gene encoding the precursor protein, preproVIP, is located on chromosome 6 
(Gozes et al, 1987), and is comprised of 7 discrete exons spanning approximately 9 kilobase 
pairs (Linder et al., 1987). PreproVIP is cleaved to synthesize the active form of VIP (Bodner, 
Fridkin, & Gozes, 1985), a 28 amino acid residue peptide that has been found to function as both 
a putative neurotransmitter, as well as a neuroendocrine hormone (Said, 1986). Given this, VIP 
has been found to exert a wide range of effects throughout the different systems of the body, the 
implications of which remain nascent in the literature, especially in regards to its binding to VIP 
specific receptors. 
VIP Tissue Distribution & Physiology 
 
VIP is expressed broadly throughout the body. It is found in neurons in both the 
peripheral and central nervous systems, as well as in several non neuronal cells extending 
throughout the immune system (Fahrenkrug, 1993). In this regard, it is both highly and diversely 
biologically active, the effects of which arise from its downstream activation of adenylyl cyclase 
and ERK signaling pathways. Broadly, VIP has been found to promote neuronal survival during 
development and apoptotic challenges (Brennemen & Eiden, 1986). Within the hypothalamus, 
particularly the suprachiasmatic nucleus (SCN), VIP expression has been correlated with light-
dark cycles, suggesting its functions in circadian rhythm regulation (Gozes, Avidor, Biegon, & 
Baldino, 1989). Within the hypothalamic-pituitary axis, VIP has also been implicated in 
facilitating the release of prolactin, oxytocin, and vasopressin (Reichlin, 1988). In the periphery, 
it is highly implicated in areas of systemic vasodilation (Said & Mutt, 1970); similarly, VIP-
mediated smooth muscle relaxation results in gastrointestinal tract relaxation (Rattan, Fan, & 
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Chakder, 1999). In some of these mechanisms, VIP works synergistically with nitric oxide (NO) 
(Grider, 1993) to inhibit the rhythmic activity (slow waves) that is exhibited at GI basal tone, 
leading to hyperpolarization and relaxation of smooth muscle (Sababi, Hallgren, & Nylander, 
1996). In the intestines, VIPergic enteric neurons can project to other enteric neurons, as well as 
muscle and epithelial cells in order to stimulate secretion (Masel, Brennan, Turner, Cullingford, 
& Cullen, 2000) and absorption (Barada, Saade, Atweh, & Nassar, 1998). In the sympathetic 
system, VIP can facilitate catecholamine release from the adrenal medulla (Malhotra, Wakade, & 
Wakade, 1988). In the immune system, VIP plays a role in regulating T cell proliferation 
(Ottaway, 1987) and can promote Th2-like immune responses (Ganea, Hooper, & Kong, 2015), 
which manifests in its endogenous anti-inflammatory action.  
VPAC Receptor Tissue Distribution 
 
VIP binds with equally high affinity as PACAP to VPAC1 and VPAC2 receptors. 
Detailed studies have found the VPAC1 receptor to be highly concentrated throughout both the 
central and peripheral nervous system. In the central nervous system, the receptor has been 
isolated in the pyrifom & cerebral cortex, lateral amygdaloid nucleus, putamen, supraoptic 
nucleus, choroid plexus, dentate gyrus, and pineal gland (Usdin, Bonner, & Mezey, 1994; 
Vertongen, Schiffmann, Gourlet, & Robberecht, 1997; Vaudry et al., 2000). In the peripheral 
nervous system, the receptor has been found in abundance in both tissues and organs, including 
the: liver, kidney, prostate, breast, spleen, lung, and GI tract (Reubi, 2000). 
Similarly, the VPAC2 receptor has also been localized to both central and peripheral 
tissue. In the CNS, presence of the VPAC2 receptor has been reported throughout the cerebral 
cortex, PVN, SCN, thalamus, hypothalamus, and amygdala (Sheward, Lutz, & Harmar, 1995; 
Vertongen et al., 1997; Vaudry et al., 2000). In peripheral tissue, the receptor has been primarily 
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associated within the smooth muscle of organs and blood vessels, but has also been demonstrated 
in pancreatic acinar cells, the adrenal medulla, retina, and lung alveoli (Harmar et al., 2004). 
Although the receptors are co-expressed in certain areas, they are often delineated to different 
layers within the same tissue. 
G-Protein Coupled Receptor Structure 
 
Both VPAC receptor variants are Type II, or Class B GPCRs, indicative of the secretin 
receptor family (May & Parsons, 2016). Similar to other classes of GPCRs, Class B GPCRs are 
structurally characterized by an N-terminus extracellular domain (ECD) and intracellular C- 
terminus tail with 7 transmembrane intervening alpha helices. These are linked by 3 extracellular 
and 3 intracellular loops. Specific to the Class II receptors is the presence of a large 
(approximately 120 amino acid) N-terminal extracellular domain that is comprised of 10 highly 
conserved amino acids. This entails six cysteine residues to form 3 disulfide bonds, N-terminal 
leader sequences (Laburthe, Couvineau, & Tan, 2007), and anti-parallel beta-sheets.  There are 
clusters of serine residues in the intracellular tail that serve as a docking site for scaffolding 
proteins (May & Parsons, 2016). 
VPAC Receptor Extracellular Binding Domain 
 
A key feature of the VPAC1 receptor is the presence of the N-terminus ECD region, 
which is thought to be essential to VIP binding. As for all N-terminus domains of Class B 
receptors, the human VPAC1 receptor ECD is thought to be comprised of two antiparallel beta 
sheets. These are stabilized by three disulfide bonds between Cys50 and Cys72, Cys63 and Cys105, 
and Cys86 and Cys122, and a salt bridge between Asp68 and Arg103, which are both constrained 
between the aromatic rings of Trp73 and Trp110 (Fig. 1). Likewise, the VPAC2 receptor reflects a 
highly similar ECD, with the exceptions of a salt bridge between Asp56 and Arg91, and both the 
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cysteine disulfide bridges and salt bridge being confined between Trp62 and Trp98 (Tan et al., 
2006). In both receptors, these residues are thought to constitute a short consensus repeat (SCR), 
comparable to a Sushi domain motif due to their presence towards the N-terminus of the receptor 
(Schwarzenbacher et al., 1999). This indicates their role in ligand recognition, apart from 
stabilization of the receptor.  
VPAC Receptor Activation 
 
There are currently two models surrounding VPAC receptor activation. The prototypical 
two domain model suggests that VIP binds to the VPAC receptors in a manner that allows 
interactions at two separate receptor sites. These include the aforementioned N-terminal ECD 
domain and a central binding domain within the juxtamembrane core of the receptor that results 
in conformational dynamics for receptor activation (Laburthe, Couvineau, & Marie, 2002). Upon 
further investigation, the carboxyl terminal and central component of VIP is thought to bind the 
receptor ECD, which orients and positions the N-terminus end of the peptide to bind the receptor 
core. This model is supported by pharmacological data, which supports the notion that N-
terminally truncated VIP analogs are common observable receptor antagonists (Laburthe, 
Couvineau, & Marie, 2002). 
Another model for several Class II GPCRs suggests that a hidden epitope may exist 
within the ECD domain. In regards to the VPAC receptors, the model suggests that VIP binds to 
the ECD, and upon binding causes a hidden epitope within the ECD region to become exposed, 
which subsequently interacts with the receptor core (Dong, Pinon, Asmann, & Miller, 2006). 
This model is currently disfavored, as it does not allow N-terminally truncated peptides to 
behave as antagonists. Further, the proposed newly exposed epitopes have consensus asparagine 
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N-glycosylation sites that would prohibit binding to the transmembrane core (Couvineau, Fabre, 
Gaudin, Maoret, & Laburthe, 1996; Tan et al., 2006).  
VPAC Receptor Signaling Cascades 
 
Upon activation, signaling cascades for both receptor subtypes are analogous. In brief, 
many Class B GPCRs exhibit similar functionality and mechanisms. Upon agonist binding to the 
extracellular binding domain on the receptor, the GPCR undergoes a conformational change to 
an active state, which mobilizes the heterotrimeric G proteins (Gα/Gβγ). Upon activation, the Gαs 
subunit exchanges GDP for GTP, dissociates from the Gβγ subunit, and stimulates adenylyl 
cyclase to catalyze ATP to cAMP (May & Parsons, 2016). In the activated receptor, the Gαs 
subunit likely docks at the intracellular face of the receptor by interacting with the third 
intracellular loop (ICL3) and C-terminal domain (Laburthe, Couvineau, & Tan, 2007). It is 
notable that unlike some class B receptors, the VPAC receptors appear to preferentially activate 
Gαs and not other G proteins such as Gαq/11 to transduce PLC as independent second messenger 
generators (May & Parsons, 2016). 
In addition to heterotrimeric mobilization, agonist binding to the extracellular binding 
domain activates G-protein receptor kinases (GRKs), predominately GRK-2, -3, which 
phosphorylate the receptor on serine and threonine residues in the third cytoplasmic loop and/or 
the C-terminal tail region. The phosphorylation at some of these sites signals β-arrestin -1, -2 
binding to the phosphorylated sites, which is necessary for receptor internalization as well as 
sterically hindering G-protein coupling and plasma membrane-delimited signaling. Of note, β-
arrestins also exhibit cAMP phosphodiesterase interactions, implying that the arrestins dually 
desensitize Gαs through subunit uncoupling and accelerated cAMP degradation (Reiter & 
Lefkowitz, 2006). β-arrestin is essential for protein scaffolding for clathrin, which is integral for 
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receptor internalization. While it was originally believed GRK-β-arrestin interactions were 
mechanisms for receptor internalization and desensitization, new evidence appears to suggest 
that the functions are more nuanced. Following β-arrestin dependent clathrin-mediated 
endocytosis, it has been shown that the complex has the ability to scaffold MAPK enzymes for 
long term MEK/ERK signaling (Clason, Girard, May, & Parsons, 2016).  
VPAC Receptor Duality 
 
It is apparent that the distinctions between the VPAC1 and VPAC2 receptors are not well 
understood. Given that they are two highly related receptors that bind the same endogenous VIP 
ligand, generate similar second messenger signals, and have evolved in parallel to each other, 
there must exist differences for evolutionary divergence. There has been a small amount of 
studies that have thus far shown small differences in receptor functioning. For example, it has 
been shown that VPAC1 receptor activation appears to inhibit GABA release, whereas VPAC2 
receptor activation enhances it (Cunha-­‐Reis, Ribeiro, Almeida, & Sebastião, 2017). It has also 
been shown that VPAC2 receptors are essential to circadian functioning in mice in comparison to 
VPAC1 receptors (Hamar et al., 2002). Conversely, VIP induced VPAC1 receptors have been 
shown to attenuate acute pancreatitis in mice, whereas VPAC2 receptors did not (Kojima et al., 
2005). However, the quantity of research into these functional differences is scarce, with even 
fewer studies examining the differences in structural/mechanistic nature of these receptors and 
implications on downstream signaling. We aimed to begin to address this deficiency using a 
panel of pharmacological compounds, including a myriad of acyl hydrazides and a previously 
described glucagon receptor antagonist, MK-0893 (Jazayeri et al., 2016). This was done in an 
effort to elucidate whether there are structural differences that distinguish their function. The 
compounds were tested on their abilities to block or alter VIP signaling in HEK-293 cells stably 
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expressing the VPAC1-EGFP or VPAC2-EGFP receptors. Phosphorylated ERK fold change was 




Stable HEK-293 cells expressing either the VPAC1-EGFP or VPAC2-EGFP receptor 
were treated for 15 minutes with a test compound (20 uM) before the addition of 25 nM VIP for 
an additional 15 minutes. The samples were subsequently lysed in lysis buffer containing 
protease and phosphatase inhibitors (May et al., 2010).  The compounds consisted of a panel of 
acyl hydrazides, previously described as PAC1 receptor antagonists, in addition to the glucagon 
receptor antagonist AB120 (MK-0893). 
Bradford Assay 
 
A standard curve was generated through the addition of BSA standards (150 uL) in 
duplicates to corresponding wells on a ninety-six well plate. The experimental samples were 
diluted 1:400 with Milli-Q water, followed by the addition of 150 uL of samples that were 
similarly added in duplicates to adjacent wells. The Coomassie PlusTM Protein Assay Reagent 
was pipetted into both standard and sample wells for colorimetric detection at 595 nm using a 
Synergy Biotech plate reader. The sample absorbance was entered into an Excel sheet to 




The samples were diluted and combined with 7.5 uL of 4x LDS and 3 uL of 10x DTT 
sample reducing agent. Samples were denatured on a heating block at 97 degrees Celsius for 10 
minutes and centrifuged down to collect droplets in the tube. Pre-cast 4-12% Bis-Tris, 12 well 
gels were used in an Invitrogen Novex Mini Cell apparatus. 1x SDS MOPS running buffer (50 
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mL 20x SDS + 950 mL Milli-Q water) was placed in both the inner and outer cores, followed by 
500 uL of antioxidant that was pipetted into the inner core. Gels were pre-run for 5 minutes. 25 
uL of sample were added to individual wells, flanked by 2 uL of SeeBlue®Plus2 standard ladder 
on the end lanes. The gel was run for approximately 60 minutes at 150 V. Upon removal, the gel 
cassette was opened, and the gel segments containing the wells and dye front were removed. 
Whatman paper that had been soaking in Transfer buffer (50 mL 20x Transfer buffer + 200 mL 
methanol + 750 mL Milli-Q water) was placed directly onto the gel; the gel was overlaid with an 
Immobilon transfer membrane (0.45 um pore) that had been pre-soaked with methanol. A second 
piece of Whatman paper was placed on top of the membrane, and the complex was gently rolled 
with a cylinder to remove trapped air bubbles. 3 filter pads soaked in transfer buffer were placed 
in a separate Novex Mini Cell transfer box holder, followed by the gel sandwich and an 
additional 3 filter pads. The box was locked into the Mini Cell and filled with transfer buffer in 
both inner and outer cores. The transfer was run for 75 minutes at 25 V. After protein transfer, 
the membrane was recovered and placed into a small box with aquablock (1:1 with PBS) on a 
platform shaker for 60 minutes. The aquablock was removed, and a 1:1000 dilution of a mouse 
pERK antibody (4 mL aquablock, 40 uL 10% Tween20, 4 uL antibody) was added. The 
membrane was incubated with gentle agitation in a cold room overnight. 
Day 2 
The membrane was removed from the cold room. 3x10 minute 1x PBST (900 mL Milli-
Q water, 100 mL 10x PBS, 1 mL Tween20) washes were performed. After washing, the blot was 
incubated in a 1:20000 dilution of a donkey anti-mouse IgG secondary antibody (15 mL 1x 
PBST, 5 mL aquablock, 1 uL antibody) for 60 minutes. A second 3x10 minute 1x PBST wash 
was performed. The blot was allowed to rest in a solution of 1x PBS (900 mL Milli-Q water, 100 
mL 10x PBS) for 5 minutes, and was analyzed using a LiCor Odyssey imager at 800 nm. Bands 
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were quantified for pERK expression and exported to an Excel program. The blot was then 
incubated in a 1:1000 dilution of a rabbit pan-ERK primary antibody (4 mL aquablock, 40 uL 
Tween20, 4 uL antibody) with gentle agitation in the cold room overnight. 
Day 3 
The membrane was removed from the cold room. 3x10 minute 1x PBST (900 mL Milli-
Q water, 100 mL 10x PBS, 1 mL Tween20) washes were performed. Upon washing, the blot was 
set in a 1:20000 dilution of a goat anti-rabbit IgG secondary antibody (15 mL 1x PBST, 5 mL 
aquablock, 1 uL antibody) for 60 minutes. A second 3x10 minute 1x PBST wash was performed. 
The blot was then rested in a solution of 1x PBS (900 mL Milli-Q water, 100 mL 1x PBS) for 5 
minutes, and was permitted to fully dry before being analyzed using the Odyssey imager at 700 
nm. Bands were quantified for total ERK expression and exported to an Excel program. 
Normalized pERK expression was calculated, and the pERK fold change was standardized to the 
control well. From sample replicates, the mean ± SEM was calculated for each treatment. 
Statistical analysis was conducted using SigmaPlot/SigmaStat 12.0 software. One-way ANOVA 
was performed followed by Student-Newman-Keuls posthoc analyses. 
Results 
Quantitative Western analyses for pERK levels were used to test the abilities of a panel 
of 13 small molecule compounds (mass ~450 Dal) to antagonize or modulate VPAC1 and 
VPAC2 receptor activation. All of the compounds, except for compound AB120, were acyl 
hydrazide analogues, some of which had been described previously as PACAP receptor 
antagonists. Compound AB120 is the glucagon receptor antagonist MK-0893 used previously to 
facilitate the determination of the glucagon receptor structure. Preliminary quantitative results 
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from Western blotting analyses suggest that I48 and AB120 exhibit positive allosteric effects in 
VPAC1 (Fig. 2) but not VPAC2 receptors (Fig. 3). 
VIP alone stimulated VPAC2 receptor pERK levels approximately 8-fold. There are 2 
forms of the ERK enzyme, p42 and p44 ERK; both forms were phosphorylated after VIP 
stimulation. To varying degrees, all 13 compounds demonstrated abilities to block VIP-
stimulated VPAC2 receptor ERK activation. Whereas compounds I54, MB216 and AB120 (MK-
0893) blocked ERK activation approximately 50%, the acyl hydrazide compounds I12, I42 and 
MB208 appeared more potent and appeared to block VIP-induced ERK signaling to control 
levels (P < 0.05; Fig. 4). 
VIP stimulation of pERK levels at the VPAC1 receptor was approximately 2-fold and 
hence less robust, which may reflect differences in VPAC1 receptor expression levels or a more 
transient nature of ERK activation. Even though several of the small molecule acyl hydrazide 
compounds in the panel, such as MB208 and I42, also appeared to behave as receptor antagonists 
and returned the VIP-stimulated ERK levels to control levels, the overall variance among 
samples precluded identification of significant statistical changes. However, acyl hydrazide I48 
and GCGR receptor antagonist AB120 (MK-0893) appeared to be strong positive allosteric 
modulators and significantly increased VIP-mediated ERK activation 4- and 7-fold from control 
levels respectively i.e. I48 and AB120 (MK-0893) compounds amplified VIP-stimulated ERK 
activation 2- and 3.5-fold above levels seen for VIP alone (P < 0.05; Fig. 4). 
Discussion 
 
We expected the preconceived antagonists to blunt ERK signaling. Contrary to this 
notion, I48 and AB120 were found to function as positive allosteric modulators of the VPAC1 
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receptor, resulting in an increase in pERK expression (and thus increased pERK fold change) 
compared to lone VIP treated cells.  
Unlike Class A GPCRs, there are currently no active structures for Class B GPCRs. Until 
recently, there has been only one defined ligand binding site for Class B GPCRs (CRF1R) that 
was found to be located deep within the TM7 bundle. However, recently Jazayeri et al. utilized 
MK-0893 (AB120), a glucagon receptor antagonist, to define a novel second binding site that 
differed from the canonical helical bundle (2016). MK-0893 was found to bind to an allosteric 
site on the GCGR in between TM6 and TM7 (Fig. 5). It is theorized that, in comparison to Class 
A GPCRs, Class B GPCRs may also mobilize upon activation by rotating and outwardly 
extending the cytoplasmic interface of TM6 to allow for G-protein binding (Deupi & Standfuss, 
2011). By binding here, MK-0893 is permitted to function as a clamp, holding TM6 in an 
inactive state (Jazayeri et al., 2016). However, although the GCGR and VPAC1 receptors are 
both categorically Class B, MK-0893 appears to have an opposite effect in VPAC1 receptors. 
MK-0893 serves as a positive allosteric modulator in VPAC1 receptors, but not VPAC2 receptors 
(Fig. 4). For VPAC2 receptors, it is both logical and likely that MK-0893 functions in a similar 
way as it does in the GCGR, holding the receptor in an inactive state and preventing VIP 
activation. Briefly, as exhibited in the GCGR, MK-0893 may connect to TM6 from within the 
lipid bilayer, causing TM6 to bisect the binding site into a hydrophobic region facing TM5 and a 
hydrophilic region oriented towards TM7. Of its numerable interactions with both regions, it is 
notable that the methoxynaphthalene (hydrophobic) and phenylethylpyrazole core (polar) 
moieties will make contact at the TM5-TM6 and TM6-TM7 interfaces with Phe3456.36b and 
Thr3536.44b respectively (Fig. 5; Jazayeri et al., 2016). However, MK-0893 binding and 
modulating effects on VPAC1 receptors is inherently more complex. 
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Due to the novel discovery of a secondary binding site, it remains unclear how MK-0893 
functions as a positive allosteric modulator to the VPAC1 receptor. Our data illustrate that MK-
0893 administration results in enhanced pERK expression (Fig. 4), indicating that the ERK 
pathway is highly active for an extended period of time. Presumably, MK-0893 binds the same 
TM6-TM7 region as in the GCGR. However, given similar pharmacodynamics, the VPAC1 
receptor molecular composition must essentially differ from that of the GCGR and VPAC2 
receptors so that the cytoplasmic interface of TM6 is favored in the outwardly extended 
conformation. This may be associated with the aforementioned Phe3456.36b and Thr3536.44b 
residues, since they are the only key binding site residues that exhibit weaker conservation across 
other Class B receptors (Jazayeri et al., 2016). Thus it is likely they are involved, to some degree, 
in the divergence of MK-0893 activity in glucagon/VPAC2 and VPAC1 receptors. Given this, it 
is probable the agent works synergistically with VIP binding to the ECD as a positive allosteric 
modulator. This is further supported by unpublished results suggesting that MK-0893 alone 
cannot stimulate downstream ERK phosphorylation; that is, it cannot function as an agonist. 
I48 is derived from the pharmacophore of all acyl hydrazides. As such, it shares almost 
identical molecular homology among MB208, I12, I48, I54 and I55. The difference in these 
structures, from which stems the different magnitudes of VPAC1 receptor activation, is localized 
to the most distal modifiable aromatic group. In I48, the distal modifiable aromatic group 
comprises a trifluoromethyl at the ortho position. This is in contrast to MB208 and I12, whose 
trifluoromethyl substituent rests at the meta and para positions respectively. This is also in 
contrast to I54, whose modifiable aromatic group is comprised of two trifluoromethyls located at 
the meta positions, and in further contrast to I55, which forgoes this moiety in exchange for a 
nitrogen dioxide located at the meta position. 
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At a glance, given the structure of I48, it would appear unlikely to bind the TM6-TM7 
region in comparison to MK-0893. Structurally, these acyl hydrazides are largely apolar and thus 
do not serve the role of bipartite interactions as well as MK-0893 does. However, unpublished 
results examining these two agents in concert with each other suggests that they do operate at the 
same allosteric binding domain. This presupposes a particular binding problem, in that it must be 
further examined how this agent orients itself within the binding site, and what binding site 
residues are essential to its docking in comparison to MK-0893. Furthermore, similar to MK-
0893, it has also been shown that none of the acyl hydrazides, including I48, have the capacity 
for agonist like effects. Thus, our results illustrate that I48 serves as solely a positive allosteric 
modulator in VPAC1 but not VPAC2 receptors, with increasing interest being placed on how the 
agent interacts with the same helical binding site as MK-0893 does. 
Given insight into both pharmacological positive allosteric modulators presented here, it 
follows that there remains significant research to be investigated. Ideally, this includes isolating a 
high resolution structure of both VPAC1 and VPAC2 receptors. However, given the longevity of 
such a project, what can be done immediately is to synthesize analogs of the acyl hydrazides to 
more closely mimic the structure of MK-0893. Comparing those results against the ones 
presented here would serve as one way in determining essential binding interactions between I48 
and the helical site. This would also permit observance of how the agent orients itself into the 
site. Additionally, time pulse experiments are essential in defining ERK activation pathways, 
given that both receptor isoforms have been shown to differentially activate ERK. Addressing 
these may aid in the discovery of novel therapeutic targets for VIP pathophysiology, such as 
VIPomas, GI distress, and hormonal regulation. 
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It may also be prudent to further investigate I12, which exhibited apparent inverse agonist 
like effects in the VPAC2 but not VPAC1 receptor. Although not statistically significant, there 
exists a qualitative discrepancy that may lend itself to further characterization of how acyl 
hydrazides bind to the helical site, given that the agents differ only in ortho or para positioning of 
the trifluoromethyl substituent. 
In addition to these agents’ effects on VIP binding to VPAC type receptors, similar 
experimentation should be performed and compared using a PACAP ligand. Given their close 
association and equal affinity binding to VPAC receptors, this would be important in classifying 
the drug-receptor binding interactions presented here as VIP specific, further differentiating the 
two endogenous ligands from one another. 
Limitations from this study result from the variance between samples that precluded 
statistically significant findings. Due to the magnitude of consistent pERK fold change resulting 
across both I48 and AB120, we find these results to retain their integrity. However, as mentioned 
above, I12 may in fact serve as an inverse agonist, and should be thoroughly reexamined. 
Additionally, VPAC1 ERK activation in lone treated VIP cells was not found to be statistically 
significant from control levels. While this may be due to a more transient level of receptor 
activation as compared to VPAC2 receptors, this should also be reexamined for the integrity of 
results presented here. 
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Figure 1. Ribbon representation of the VPAC1 extracellular binding domain. Three essential 
binding moieties are presented. A) Representation of β sheet (yellow) and three essential 
disulfide bonds (green). B) Representation of salt bridge (red) confined between tryptophan 
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Figure 2. Acyl hydrazide I48 and GCGR antagonist AB-120 (MK-0893) act as positive allosteric 
modulators of VIP-induced ERK phosphorylation. Representative Western blot analysis of Plate 
1 (A) and Plate 2 (B). VPAC1 receptor cell cultures were treated with VIP (25 nM) for 15 
minutes. Other cell cultures were pretreated with a panel of pharmacological agents (20 uM) for 
15 minutes before exposure to VIP for an additional 15 min. 
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Figure 3. Acyl hydrazide I48 and GCGR antagonist AB-120 (MK-0893) do not act as positive 
allosteric modulators of VIP-induced ERK phosphorylation. Representative Western blot 
analysis of Plate 1 (A) and Plate 2 (B). VPAC2 receptor cell cultures were treated with VIP (25 
nM) for 15 minutes. Other cell cultures were pretreated with a panel of pharmacological agents 
(20 uM) for 15 minutes before exposure to VIP for an additional 15 min. 
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Figure 4. Quantification of phosphorylated ERK in VPAC1 and VPAC2 receptors. pERK was 
normalized to total ERK in each sample. VIP alone stimulated ERK activation ~2-fold in VPAC1 
receptors compared to control. Following pretreatment with I48 and AB-120, the VIP-induced 
ERK phosphorylation increased significantly ~4 and ~7-fold from control levels respectively. In 
contrast, in VPAC2 receptors, VIP alone stimulated pERK levels ~8-fold from control levels. 
Pretreatment with I48 and AB-120 did not significantly increase the VIP-induced ERK 
phosphorylation. Data represent mean fold change ±SE; n=3 independent experiments different 
from control and lone VIP treated samples, all at P < 0.05.  
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Figure 5. Glucagon receptor sequence and structure. a) Glucagon receptor transmembrane 
domain amino acid arrangement. b) MK-0893 structure. c) GCGR ribbon representation of MK-
0893 binding at the helical site, transmembrane orientation. d) GCGR, top view from 
extracellular face demonstrating MK-0893 pincher to restrict TM6 dynamics. e) MK-0893 
modeled in the lipid bilayer (taken from Jazayeri et al., 2016).  
